Compare TROX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | NBTX |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2012 | 2018 |
| Metric | TROX | NBTX |
|---|---|---|
| Price | $6.50 | $34.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $6.07 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 4.3M | 38.2K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,898,000,000.00 | N/A |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $4.86 | $11.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $2.95 |
| 52 Week High | $8.80 | $37.11 |
| Indicator | TROX | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 68.93 |
| Support Level | $4.98 | $20.11 |
| Resistance Level | $6.96 | N/A |
| Average True Range (ATR) | 0.62 | 2.03 |
| MACD | -0.14 | 0.81 |
| Stochastic Oscillator | 6.78 | 76.70 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.